Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, have published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research. The new compound was named AOH1996.

In the clinical research, AOH1996 has demonstrated a good therapeutic effect on a variety of cancer cells, including breast, prostate, brain, ovarian, cervical, skin and lung cancer.

As a next step, the researchers will look to better understand the mechanism of action to further improve the ongoing clinical trial in humans.

The Shengnuo family, as the official referral partner of the Hope City National Medical Center in China, immediately sought confirmation from the Hope City National Medical Center. It was learned from the hospital that the Phase 1 clinical trial is currently open to the public, and 8 patients were recruited for the first phase. This means that domestic solid tumor patients also have the opportunity to participate.